Get Permission Joy, Ajith Kumar K C, Ramesh, Nafeesa, Jayasree, Reghunath, and Mathamkuth: Specialized pro-resolving mediators - Key players in resolution


Introduction

Inflammation is an essential mechanism in human health and diseases. Roman scientist Cornelius Celsus in the 1st century defined the clinical signs of inflammation. Initially, four cardinal signs of inflammation were identified; rubor et tumor cum calore et dolore (redness, swelling with heat and pain) in 1858. In 1958, Virchow on cellular basis of inflammation as a pathologic condition, added a new cardinal sign, functio laesa (loss of origin/tissue function). 1, 2

The primary goal of the inflammatory response is to detect and eliminate functions that interfere with homeostasis. A typical inflammatory response consists of 4 components. Inflammatory inducers, detecting sensors, downstream mediators, and the target tissues. 3, 4 Resolution of inflammation is an active process and this process is normally maintained by endogenous mediators – Specialized pro-resolving mediators.(SPMs). 5, 6, 7 (Figure 1)

These are a group of fatty acids, an essential part of the cell membrane and act as metabolic fluid for mammalian tissue. They also function as signalling molecules. Omega -6 fatty acid (Linoleic acid-LA) and omega -3 fatty acid (Linolenic acid-ALA) are essential fatty acids that cannot be biosynthesized by humans/ other animals. LA and ALA undergo sequential desaturation reaction and transform into their higher form which are in their unsaturated form. Arachidonic acid (A.A) is formed from LA and EPA (eicosapentaenoic acid), and DHA (docosahexaenoic acid) from ALA. 8, 9

The pro-resolving lipid mediators include Lipoxins, Protectins, Resolvins and Maresins. Lipoxins (LXs) and aspirin triggered lipoxins (ATLs) are formed from arachidonic acid which mainly decrease inflammation and assist resolution. Omega-3 FA is the source of resolvins, maresins and protectins. 8 (Figure 2)

Figure 1

Resolution of natural inflammation

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/1100d016-aca7-4b4c-bbb5-0fb086807999image1.png
Figure 2

Biosynthesis of lipid mediators

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/1100d016-aca7-4b4c-bbb5-0fb086807999image2.png

Discussion

Lipoxins

They are natural pro-resolving mediators derived from endogenous F.A. They have strong dual actions, i.e. anti-inflammatory and resolution actions. The first identified lipoxins are lipoxin A4 and B4. 10, 11

Biosynthesis of lipoxin- 3 main pathways has been identified. 12

  1. In blood vessels- Human platelets do not have the ability to produce lipoxins on their own, but become the major source of lipoxin, when they adhere to PMNs (polymorphonuclear neutrophils), i.e. the formation of lipoxin is initiated by platelet-leukocyte interactions. Initially, there is transcellular conversion of 5-LO (lipoxygenases-LOs) product, LTA4(leukotriene A4). When platelet get adhere, 12-LO converts this LTA4 into lipoxin A4 and B4(LXA4 and LXB4 – positional isomers).

  2. Classical pathway- In human mucosal tissue, GI tract, oral cavity, the sequential oxygenation of A.A by 15-LO and 5-LO followed by enzymatic hydrolysis leads to the production of lipoxin A4 and B4, i.e. when epithelial cells get activated, they generate and release 15S-HETE (hydroxy-eicosatetraenoic acids), that is taken up by the PMN and converted to lipoxin with help of 5-LO.Figure 3)Ecosanoid class switch – during inflammation, when there is PMN infiltration, there is coordinated coincidence of LT and PMN, which is associated with spontaneous resolution of the condition. When human blood PMN is exposed to PGE2(prostaglandins), which triggers eicosanoid class switch by regulating 15-LO. These event block LTs(leukotrienes) formation, thereby regulates leukocytes, PGD2 and HETE .12 (Figure 3)

  3. The synthetic pathway by aspirin is mainly seen in cells that bear COX-2 like vascular endothelial cells, epithelial cells, monocytes and macrophages. When aspirin is administered during inflammation, the stimuli induce COX-2 to generate 15R-HETE, this is rapidly converted to 15-epimeric-LX / aspirin triggered by lipoxins by 5-LO. 13, 14, 15 (Figure 4)

Figure 3

Lipoxin formation by transcellular biosynthesis

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/1100d016-aca7-4b4c-bbb5-0fb086807999image3.png

Figure 4

Generation of ATL mediators

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/1100d016-aca7-4b4c-bbb5-0fb086807999image4.png

Cellular functions of lipoxins

  1. Decreases adherence of leukocytes

  2. Reduces vascular leakage.

  3. Lowers prostaglandin E2 levels in exudates.

  4. Reduces the number of apoptotic neutrophils.

  5. Inhibit neutrophil recruitments.

  6. Attenuates expression of the nuclear factor kappa B gene.

  7. Blocks leukocyte adhesion protein-1 and chemotaxis

  8. Promotes lymphatic removal of phagocytes

  9. Inhibits T- cell adhesion to vascular and salivary epithelium.

  10. Enhances microbial phagocytic function. 16

Resolvins

These are endogenous lipid mediators produced during the resolution phase of acute inflammation from essential fatty acid (EPA – eicosapentaenoic acid & DHA- docosahexaenoic acid). Two series of resolvins are there, E series from EPA and D series from DHA. 17, 18

Biosynthesis of resolvins

The first bioactive molecule identified among resolvins is RvE1- Resolvin E1. Vascular endothelial cells initiate the biosynthesis through 2 pathways.

  1. Aspirin modified COX-2 coverts EPA into 18R-hydroperoxy-eicosapentaenoic acid (18R-HPEPE) and 18S-hydroperoxy-eicosapentaenoic acid (18S-HPEPE). Aspirin impacts the formation of Resolvin E1 by acetylating COX-2 in vascular endothelial cells, that stereo selectively generate 18R-HPEPE. This is taken up by human monocytes and metabolized to RvE1 and RvE2 by leukocytes 5-LO. (Figure 5)

  2. Resolvin D is formed from DHA. The LOX product 17S-hydroxy-DHA (17S-HDHA) which is rapidly transformed by the LOX activity in human PMNs into 2 epoxides intermediate. This open to form a bioactive product – 17S resolving series (RvD series). 19, 20 (Figure 6)

Functions of resolvin E1 6, 17, 21

  1. Inhibits neutrophil infiltration

  2. Modulates chemokine/cytokine synthesis

  3. Promotes healing of inflamed tissues and bone regeneration

  4. Enhances phagocytosis

  5. Activates lymphatic removal of phagocytes

  6. Attenuates systemic production of c- reactive protein and interleukin-1

  7. Reduces eosinophil and lymphocyte recruitment

  8. Regulates adipokines.

  9. Decreases inflammatory actions of COX-2

  10. Attenuates expression of the nuclear factor kappa-B gene

  11. Reduces the monocytes concentration

  12. Increases CD55 expression on epithelial cell and PMN cell clearance

  13. Rescues impaired phagocytosis in LAP patient macrophages

  14. Prevents rejection of allografts

  15. Activates anti-apoptotic signals.

Functions of resolvin D1 22, 23

  1. Inhibits neutrophil recruitment

  2. Anti-hyperalgesic properties

  3. Shortens resolution interval

  4. Reduces oxidative stress-mediated inflammation

  5. Attenuates agonist pain molecules

  6. Induces macrophage phagocytosis

  7. Stimulates M2 macrophage phenotype

  8. Temporally regulates micro RNAs

  9. Reduces cytokines in broncho alveolar lavage fluid

  10. Ameliorates insulin sensitivity

  11. Enhances microbial clearance

  12. Reduces level of prostaglandins and leukotrienes.

Figure 5

E-series resolvin biosynthesis

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/1100d016-aca7-4b4c-bbb5-0fb086807999image5.png
Figure 6

D-series resolvin biosynthesis

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/1100d016-aca7-4b4c-bbb5-0fb086807999image6.png

Protectins

Endogenous lipid mediators, also called as neuroprotectins, account for the protective actions observed in neural tissues and within the immune system.

Biosynthesis

Endogenously produced DHA is converted into triene containing conjugated structure via LOX pathway defines the key feature of the family derived from DHA. LOX product 17S-H(p)DHA undergoes enzymatic epoxidation to 16(17)-epoxide, that is enzymatically converted to 10,17 dihydroxy containing bioactive product- 10R,17S diDHA, NPD1/PD1 – protectins/ neuroprotection. 24, 25 (Figure 7)

Human peripheral blood lymphocytes also have the ability to produce protectin D1 with a Th2 phenotype there by reducing TNF-α and interferon γ secretion, and thereby blocking T cell migration and promoting T cell apoptosis. 26

Figure 7

Biosynthesis of protectins

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/1100d016-aca7-4b4c-bbb5-0fb086807999image7.png

Functions 17, 27

  1. Decreases inflammatory actions of COX-2

  2. Inhibits neutrophil infiltration

  3. Modulates chemokine/cytokine synthesis

  4. Regulates T-cell migration

  5. Regulates macrophage function

  6. Upregulates CCRS expression on apoptotic leukocytes

  7. Prevents hepatocyte steatosis

  8. Inhibits pain signals

  9. Suppresses eosinophil chemotaxis and adhesion.

Maresins

They are macrophage mediators in resolution of inflammation, primary molecules produced by macrophages with homeostatic function. They are the third largest family of SPMs derived from DHA 20. 6, 28

Biosynthesis

  1. It occurs mainly in M2 macrophages and is initiated by human macrophage 12- lipoxygenase (12-LO).

  2. Initially, DHA is converted enzymatically into14-hydroxyDHA intermediate. This requires the addition of oxygen atom into DHA at the 14th carbon atom. This give rise to 14S- H(p)DHA, which is further metabolized to 13S, 14S- epoxide maresin, again undergoes enzymatic hydrolysis to form maresin-1. 20 (Figure 8)

Figure 8

Biosynthesis of maresins

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/1100d016-aca7-4b4c-bbb5-0fb086807999image8.png

Functions 29

  1. Reduces neutrophil number in exudate

  2. Enhances macrophage phagocytic functions

  3. Decreases trans endothelial polymorphonuclear cell migration

Conclusion

Acute inflammation serves to protect the host and is primarily initiated by neutrophils in response to a challenge. The outcome of inflammation depends on a balance between factors that either amplify the inflammatory response or promote its resolution. Recent insights reveal that the resolution of inflammation is regulated by protective mediators such as lipoxins derived from arachidonic acid, aspirin-triggered lipoxins, E-series resolvins derived from eicosapentaenoic acid, D-series resolvins derived from docosahexaenoic acid, protectins, and maresins.

These lipid mediators interact with G protein-coupled receptors on innate immune cells to facilitate several processes: they halt leukocyte infiltration, restore normal vascular permeability and reduce edema, promote the apoptosis of polymorphonuclear neutrophils, encourage the non-inflammatory infiltration of monocytes/macrophages, and assist macrophages in clearing apoptotic neutrophils, bacteria, and necrotic debris from the affected area. Through these processes, inflammation resolves effectively, leading to a return to homeostasis.

Source of Funding

None.

Conflicts of Interest

None.

References

1 

R Virchow Cellular pathology, as based upon physiological and pathological histology : twenty lectures delivered in the Pathological Institute of Berlin during the months of February, March and April, 1858R.M. De WittNew York1858

2 

MO Freire TE Van Dyke Natural resolution of inflammationPeriodontol 2000200063114964

3 

R Medzhitov Inflammation 2010: new adventures of an old flameCell201014067716

4 

I M Fierro C N Serhan Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxinsBraz J Med Biol Res200134555566

5 

MO Freire TE Van Dyke Natural resolution of inflammationPeriodontol200063114964

6 

CN Serhan CB Clish J Brannon SP Colgan N Chiang K Gronert Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2- nonsteroidal antiinflammatory drugs and transcellular processingJ Exp Med200019281197204

7 

TE Van Dyke Inflammation and periodontal diseases: a reappraisalJ Periodontol200879815012

8 

TE Van Dyke CN Serhan Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseasesJ Dent Res20038228290

9 

CN Serhan A search for endogenous mechanisms of anti_inflammation uncovers novel chemical mediators: missing links to resolutionHistochem Cell Biol2004122430521

10 

JG Filep C Zouki NA Petasis M Hachicha CN Serhan Anti-inflammatory actions of lipoxin A(4) stable analogs are demonstrable in human whole blood: modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactionsBlood19999412413242

11 

C Godson S Mitchell K Harvey NA Petasis N Hogg HR Brady Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophagesJ Immunol2000164416637

12 

CN Serhan N Chiang Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entrée for resoleomicsRheum Dis Clin North Am20043016995

13 

BD Levy CB Clish B Schmidt K Gronert CN Serhan Lipid mediator class switching during acute inflammation: sig_nals in resolutionNat Immunol2001276129

14 

CN Serhan Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolutionProstaglandins Other Lipid Mediat200268-694335510.1016/s0090-6980(02)00047-3

15 

AT Gewirtz VV Fokin NA Petasis CN Serhan JL Madara LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulationAm J Physiol1999276498894

16 

CN Serhan N Chiang J Dalli BD Levy Lipid Mediators in the Resolution of InflammationCold Spring Harb Perspect Biol201472a01631110.1101/cshperspect.a016311

17 

GL Bannenberg N Chiang A Ariel M Arita E Tjonahen KH Gotlinger Molecular circuits of resolution: formation and actions of resolvins and protec_tinsJ Immunol20051747434555

18 

R Yang N Chiang SF Oh CN Serhan Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytesCurr Protoc Immunol2011142610.1002/0471142735.im1426s95

19 

CN Serhan N Chiang Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genusBr J Pharmacol2008153120015

20 

CN Serhan Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolv_ing mediatorsJ Thromb Haemost200971448

21 

TE Van Dyke Cellular and molecular susceptibility determinants for periodontitisPeriodontol 200020004510310.1111/j.1600-0757.2007.00228.x

22 

S Hong K Gronert PR Devchand RL Moussignac CN Serhan Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cellsJ Biol Chem2003278171467787

23 

N Chiang G Fredman F Backhed SF Oh T Vickery BA Schmidt Infection regulates pro-resolving mediators that lower antibiotic requirementsNature201248473955248

24 

GL Bannenberg N Chiang A Ariel M Arita E Tjonahen KH Gotlinger Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins1J Immunol20051747434555

25 

P Chen B Fenet S Michaud Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregationFEBS Lett200958321347884

26 

VL Marcheselli PK Mukherjee M Arita S Hong R Antony K Sheets Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophilsProstaglandins Leukot Essent Fatty Acids20108212734

27 

JM Schwab N Chiang M Arita CN Serhan Resolvin E1 and protectin D1 activate inflammation-resolution pro_grammesNature2007447714686974

28 

HB Gireddy H Rajaram RR Koduganti M Ambati R Anilkumar TSL Harika Maresins: The Mainstay in Periodontal ResolutionCureus20221412174210.7759/cureus.21742

29 

M Shinohara V Mirakaj C N Serhan Functional metabolo_mics reveals novel active products in the DHA metabolo_meFront Immunol201238110.3389/fimmu.2012.00081



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 05-07-2024

Accepted : 30-08-2024


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijpi.2024.030


Article Metrics






Article Access statistics

Viewed: 189

PDF Downloaded: 42



Medical Abbreviation List